Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) U.S. — Organic / Comparable Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, Q3 2026
9.0%
Period ended Sep 30, 2026
Change on a year earlier
-12.1 pts
21.1% in Q3 2025
History
38 quarters
Since Q1 2017
Sources
38
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) U.S. — Organic / Comparable Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 9.0% | -12.1 pts | SEC Filing (0001628280-26-066601) ↗ |
| Q2 2026 | Jun 30, 2026 | 10.7% | -5.8 pts | SEC Filing (0001628280-26-048377) ↗ |
| Q1 2026 | Mar 31, 2026 | 11.5% | -0.8 pts | SEC Filing (0001628280-26-025365) ↗ |
| Q4 2025 | Dec 31, 2025 | 12.8% | +6.8 pts | SEC Filing (0001628280-26-002982) ↗ |
| Q3 2025 | Sep 30, 2025 | 21.1% | +15.1 pts | SEC Filing (0001628280-25-045049) ↗ |
| Q2 2025 | Jun 30, 2025 | 16.5% | +8.0 pts | SEC Filing (0001628280-25-035135) ↗ |
| Q1 2025 | Mar 31, 2025 | 12.3% | +7.8 pts | SEC Filing (0001628280-25-017924) ↗ |
| Q4 2024 | Dec 31, 2024 | 6.0% | -6.0 pts | SEC Filing (0001628280-25-002092) ↗ |
| Q3 2024 | Sep 30, 2024 | 6.0% | +2.3 pts | SEC Filing (0001628280-24-042893) ↗ |
| Q2 2024 | Jun 30, 2024 | 8.5% | +6.5 pts | SEC Filing (0001628280-24-032182) ↗ |
| Q1 2024 | Mar 31, 2024 | 4.5% | – | SEC Filing (0001628280-24-016497) ↗ |
| Q4 2023 | Dec 31, 2023 | 12.0% | +6.8 pts | SEC Filing (0001628280-24-002009) ↗ |
| Q3 2023 | Sep 30, 2023 | 3.7% | +4.7 pts | SEC Filing (0001628280-23-034544) ↗ |
| Q2 2023 | Jun 30, 2023 | 2.0% | +4.3 pts | SEC Filing (0001628280-23-025156) ↗ |
| Q4 2022 | Dec 31, 2022 | 5.2% | +7.9 pts | SEC Filing (0001628280-23-001516) ↗ |
| Q3 2022 | Sep 30, 2022 | -1.0% | -10.6 pts | SEC Filing (0001628280-22-026588) ↗ |
| Q2 2022 | Jun 30, 2022 | -2.3% | -48.3 pts | SEC Filing (0001104659-22-081006) ↗ |
| Q1 2022 | Mar 31, 2022 | 3.1% | -2.5 pts | SEC Filing (0001104659-22-047560) ↗ |
| Q4 2021 | Dec 31, 2021 | -2.7% | +4.1 pts | SEC Filing (0001104659-22-007648) ↗ |
| Q3 2021 | Sep 30, 2021 | 9.6% | +18.3 pts | SEC Filing (0001104659-21-127874) ↗ |
| Q2 2021 | Jun 30, 2021 | 46.0% | +78.2 pts | SEC Filing (0001104659-21-094680) ↗ |
| Q1 2021 | Mar 31, 2021 | 5.6% | +15.0 pts | SEC Filing (0001104659-21-052205) ↗ |
| Q4 2020 | Dec 31, 2020 | -6.8% | -8.6 pts | SEC Filing (0001104659-21-007942) ↗ |
| Q3 2020 | Sep 30, 2020 | -8.7% | -6.4 pts | SEC Filing (0001104659-20-116611) ↗ |
| Q2 2020 | Jun 30, 2020 | -32.2% | -27.8 pts | SEC Filing (0001104659-20-083929) ↗ |
| Q1 2020 | Mar 31, 2020 | -9.4% | +2.2 pts | SEC Filing (0001104659-20-047187) ↗ |
| Q4 2019 | Dec 31, 2019 | 1.8% | +4.4 pts | SEC Filing (0001104659-20-005717) ↗ |
| Q3 2019 | Sep 30, 2019 | -2.3% | -2.9 pts | SEC Filing (0001104659-19-054283) ↗ |
| Q2 2019 | Jun 30, 2019 | -4.4% | -0.8 pts | SEC Filing (0001104659-19-040664) ↗ |
| Q1 2019 | Mar 31, 2019 | -11.6% | -12.9 pts | SEC Filing (0001104659-19-021809) ↗ |
| Q4 2018 | Dec 31, 2018 | -2.6% | -8.4 pts | SEC Filing (0001104659-19-002848) ↗ |
| Q3 2018 | Sep 30, 2018 | 0.6% | +16.2 pts | SEC Filing (0001104659-18-062380) ↗ |
| Q2 2018 | Jun 30, 2018 | -3.6% | +10.1 pts | SEC Filing (0001104659-18-045642) ↗ |
| Q1 2018 | Mar 31, 2018 | 1.3% | +19.1 pts | SEC Filing (0001104659-18-024701) ↗ |
| Q4 2017 | Dec 31, 2017 | 5.8% | – | SEC Filing (0001104659-18-003691) ↗ |
| Q3 2017 | Sep 30, 2017 | -15.6% | – | SEC Filing (0001104659-17-062667) ↗ |
| Q2 2017 | Jun 30, 2017 | -13.7% | – | SEC Filing (0001104659-17-045904) ↗ |
| Q1 2017 | Mar 31, 2017 | -17.8% | – | SEC Filing (0001104659-17-024344) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) U.S. — Organic / Comparable Sales Growth (%) (%), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-rm-yoy-org-us
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.